Niemann-Pick Type C (NPC) is a genetic disorder that leads to severe neurological decline and is difficult to diagnose, with currently no approved treatment. Recent trials with the drug miglustat showed some improvements in symptoms for patients, while research into stem cell therapy, including intra-cranial transplants, is ongoing and has demonstrated early positive outcomes in a patient named Aaditya. The hope for NPC children lies in advances in both pharmaceutical and stem cell therapies to improve their quality of life and potentially find a cure.